Update shared on 01 Dec 2025
Fair value Increased 0.28%Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook.
Analyst Commentary
Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.
Bullish Takeaways- Bullish analysts are encouraged by Owlet’s strong quarterly performance, which they consider a validation of the company’s strategic direction and operational execution.
- The additional liquidity from the recent stock offering is seen as a significant advantage. Analysts highlight this ensures ample resources for continued research and development, particularly through 2026.
- The company’s position as the only FDA-approved over-the-counter infant monitoring device is recognized as a key competitive advantage. This is especially relevant in light of the recent FDA communication highlighting risks associated with unauthorized devices.
- This regulatory clarity is seen as reinforcing Owlet’s market leadership and providing support for potential future growth, which contributes positively to its improved valuation outlook.
- Some analysts maintain a cautious stance. They note that while increased liquidity is promising, sustained investments in R&D must translate into new products or technological advances to justify elevated valuations.
- There are still questions around broader market adoption and long-term execution risks as competitors seek FDA approval to close the regulatory gap.
- Potential headwinds from regulatory changes or evolving healthcare guidelines could impact Owlet's future growth trajectory.
What's in the News
- Owlet announced partnerships with Locus Health and Rhapsody to integrate FDA-cleared BabySat® data into leading health platforms and electronic health records, giving providers secure, ongoing access to infant health data after hospital discharge (Key Developments).
- The company provided updated financial guidance for 2025, expecting revenue to reach $103 to $106 million, reflecting anticipated year-over-year growth of 32% to 36% (Key Developments).
- Regulatory approval from the Central Drugs Standard Control Organization (CDSCO) paves the way for Owlet’s Dream Sock, Dream Sight, and Dream Duo products to launch in the Indian market in early 2026 (Key Developments).
- Class action settlements have been proposed to resolve securities litigation relating to Owlet, totaling $5.25 million in cash, with a hearing scheduled for February 2026 (Key Developments).
- Owlet launched new products including the Dream Sight™ HD video monitor and next-generation Dream Duo™, expanding its smart monitoring solutions portfolio in the U.S., Canada, UK, and Europe (Key Developments).
Valuation Changes
- Fair Value: Increased modestly from $14.83 to $14.88.
- Discount Rate: Decreased slightly from 7.87% to 7.85%.
- Revenue Growth: Risen slightly, moving from 25.8% to 26.0%.
- Net Profit Margin: Declined marginally from 10.70% to 10.65%.
- Future P/E: Edged up slightly from 28.94x to 29.00x.
Have other thoughts on Owlet?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.